PURE Bioscience Sets Fiscal 2018 Q1 Financial Results Conference Call

Food Safety Solutions Update on PURE® Hard Surface and
PURE Control® Antimicrobials

SAN DIEGO–(BUSINESS WIRE)–$PURE #PURE–PURE Bioscience, Inc. (OTCQB:
PURE), creator of the patented, non-toxic silver dihydrogen citrate
(SDC) antimicrobial, announced today that on December 14, 2017 the
Company will file its Form 10-Q shortly after the close of the market
and will host an investor conference call that day at 1:30pm PST (4:30pm
EST) to review fiscal 2018 Q1 financial results.

PURE management will also discuss the progress made to commercialize its
two antimicrobial SDC-based food safety solutions:

• PURE® Hard Surface disinfectant – The status of ongoing
commercialization in restaurant chains (including Chipotle Mexican
Grill); processors/manufacturers; and food transportation.

• PURE Control® – The status of ongoing sales and marketing of FDA
approved processing aid for fresh produce; the status of the USDA
in-plant trials for use as a raw poultry processing aid.

The Participant Dial-In Number for the conference call is 1-631-891-4304.
Participants should dial in to the call at least five minutes before
1:30pm PST (4:30pm EST) on December 14, 2017. The call can also be
accessed “live” online at http://public.viavid.com/index.php?id=127392.

A replay of the recorded call will be available for 90 days on the
Company’s website (http://www.purebio.com/investors/events-presentations/).
You can also listen to a replay of the call by dialing 1-844-512-2921 (international
participants dial 1-412-317-6671) starting December 14, 2017, at 7:30pm
EST through December 21, 2017 at 11:59 pm EST. Please use PIN Number
10003983.

About PURE Bioscience, Inc.

PURE Bioscience, Inc. is focused on developing and commercializing our
proprietary antimicrobial products primarily in the food safety arena —
providing solutions to the health and environmental challenges of
pathogen and hygienic control. Our technology platform is based on
patented stabilized ionic silver, and our initial products contain
silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic
antimicrobial agent, which offers 24-hour residual protection and
formulates well with other compounds. As a platform technology, SDC is
distinguished from existing products in the marketplace because of its
superior efficacy, reduced toxicity and it mitigates bacterial
resistance. PURE is headquartered in El Cajon, California (San Diego
metropolitan area). Additional information on PURE is available at www.purebio.com.

Forward-looking Statements

Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements as that term
is defined in the Private Securities Litigation Reform Act of 1995.
Forward-looking statements inherently involve risks and uncertainties
that could cause our actual results to differ materially from any
forward-looking statements. Factors that could cause or contribute to
such differences include, but are not limited to, the Company’s failure
to implement or otherwise achieve the benefits of its proposed business
initiatives and plans; acceptance of the Company's current and future
products and services in the marketplace, including the Company’s
ability to convert successful evaluations and tests for PURE Control
into customer orders and customers continuing to place product orders as
expected and to expand their use of the Company’s products; the ability
of the Company to develop effective new products and receive required
regulatory approvals for such products, including the required data and
regulatory approvals required to use its SDC-based technology as a
direct food contact processing aid in raw meat processing and to expand
its use in OLR poultry processing; competitive factors, including
customer acceptance of the Company’s SDC-based products that are
typically more expensive than existing treatment chemicals; dependence
upon third-party vendors, including to manufacture its products; and
other risks detailed in the Company's periodic report filings with the
Securities and Exchange Commission (the SEC), including its Form 10-K
for the fiscal year ended July 31, 2017. You should not place undue
reliance on these forward-looking statements, which speak only as of the
date of this press release. By making these forward-looking statements,
the Company undertakes no obligation to update these statements for
revisions or changes after the date of this release.

Contacts

PURE Bioscience, Inc.
Hank Lambert, CEO
619-596-8600 ext. 103
[email protected]
or
Bibicoff
+ MacInnis, Inc.
Terri MacInnis, VP of IR
818-379-8500
[email protected]
or
Redwood
Investment Group
Tom Hemingway
714-978-4425
[email protected]